Mark A. Rubin
YOU?
Author Swipe
View article: Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs
Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs Open
Background The dog is the only large mammal, other than humans, that commonly develops spontaneous prostate cancer (PCa) and is, therefore, considered a valuable model for comparative studies. Estrogens are critical for normal prostate dev…
View article: Predictive molecular alterations of prostate cancer brain metastases based on a companion diagnostic assay
Predictive molecular alterations of prostate cancer brain metastases based on a companion diagnostic assay Open
The current first-line treatment standard for patients with metastatic prostate cancer (mPCa), is a combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), plus the addition of docetaxel for fit p…
View article: Preregistration does not improve the transparent evaluation of severity in Popper’s philosophy of science or when deviations are allowed
Preregistration does not improve the transparent evaluation of severity in Popper’s philosophy of science or when deviations are allowed Open
One justification for preregistering research hypotheses, methods, and analyses is that it improves the transparent evaluation of the severity of hypothesis tests. In this article, I consider two cases in which preregistration does not imp…
View article: Preregistration does not improve the transparent evaluation of severity in Popper’s philosophy of science or when deviations are allowed.
Preregistration does not improve the transparent evaluation of severity in Popper’s philosophy of science or when deviations are allowed. Open
One justification for preregistering research hypotheses, methods, and analyses is that it improves the transparent evaluation of the severity of hypothesis tests. In this article, I consider two cases in which preregistration does not imp…
View article: The interplay of social context and personal attributes in immigrants' adaptation and satisfaction with the move to Australia
The interplay of social context and personal attributes in immigrants' adaptation and satisfaction with the move to Australia Open
Previous psychological research into immigration has tended to focus either on immigrants' adjustive behaviours, such as their acculturation preference, or on community attitudes towards immigrants. Recent models bring these lines of resea…
View article: Data from ATAD2 Drives Prostate Cancer Progression to Metastasis
Data from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Metastasis accounts for the overwhelming majority of cancer deaths. In prostate cancer and many other solid tumors, progression to metastasis is associated with drastically reduced survival outcomes, yet the mechanisms behind this progress…
View article: Supplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Additional analysis of ATAD2 expression in prostate cancer.
View article: Supplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Additional analyses related to Figure 4
View article: Supplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Uncropped western blots
View article: Supplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Additional analyses related to Figure 3.
View article: Supplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Additional analyses of MYC regulation of ATAD2.
View article: Supplementary Table S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Table S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Oligonucleotides used in this Study
View article: Supplementary Table S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Supplementary Table S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Characteristics of GEMM cohort used and raw quantification of ATAD2 expression
View article: ATAD2 Drives Prostate Cancer Progression to Metastasis
ATAD2 Drives Prostate Cancer Progression to Metastasis Open
Metastasis accounts for the overwhelming majority of cancer deaths. In prostate cancer and many other solid tumors, progression to metastasis is associated with drastically reduced survival outcomes, yet the mechanisms behind this progress…
View article: Supplementary Figure 3 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 3 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 3. Example case 3.
View article: Supplementary Information 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Information 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Information 1. Post-workshop survey questions.
View article: Data from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Data from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a mechanism of treatment …
View article: Supplementary Figure 2 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 2 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 2. Example case 2.
View article: Supplementary Figure 4 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 4 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 4. Example case 4.
View article: Supplementary Figure 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 1. Example case 1.
View article: Supplementary Figure S7 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer
Supplementary Figure S7 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer Open
Figure S7. Immunohistochemical staining of CK5-PipPten model.
View article: Supplementary Table S3 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer
Supplementary Table S3 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer Open
Table S3. Crowley et al. markers for scRNA-Seq module scores
View article: Supplementary Figure S6 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer
Supplementary Figure S6 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer Open
Figure S6. Prostate morphology resulting from genomic loss of Pip4k2b isoform.
View article: Supplementary Table S1 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer
Supplementary Table S1 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer Open
Table S1. Summary of genetically engineered mouse models (GEMMs)
View article: Supplementary Figure S2 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer
Supplementary Figure S2 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer Open
Figure S2. PI5P4Kα expression enriched in basal compartment.
View article: Supplementary Figure S4 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer
Supplementary Figure S4 from Loss of PI5P4Kα Slows the Progression of a <i>Pten</i> Mutant Basal Cell Model of Prostate Cancer Open
Figure S4. Top ten differentially expressed genes in scRNA-Seq clusters.